Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 18 2015 - 4:00PM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced that it is commencing an
underwritten registered public offering of 7,250,000 shares of its
common stock. Momenta expects to grant the underwriters of the
offering an option to purchase up to an additional 1,087,500 shares
of its common stock, exercisable for 30 days. All of the shares in
the proposed offering are to be sold by Momenta.
Goldman, Sachs & Co. and J.P. Morgan are acting as joint
book-running managers for the offering. Stifel is acting as lead
manager.
The offering is being made pursuant to an effective shelf
registration statement on Form S-3 that was initially filed with
the U.S. Securities and Exchange Commission (SEC) on April 30,
2013. A preliminary prospectus supplement describing the terms of
the offering will be filed with the SEC and will form a part of the
effective registration statement. Copies of the preliminary
prospectus supplement and accompanying prospectus relating to the
offering may be obtained, when available, by contacting Goldman,
Sachs & Co., Attention: Prospectus Department, 200 West Street,
New York, New York 10282, or by telephone at (866) 471-2526 or
e-mail at prospectus-ny@ny.email.gs.com or J.P. Morgan Securities
LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717, Phone: (866) 803-9204 or e-mail
at prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
shares of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024